Research programme: urokinase plasminogen activator inhibitors - Wilex

Drug Profile

Research programme: urokinase plasminogen activator inhibitors - Wilex

Alternative Names: uPA inhibitors - Wilex; WX 508; WX 678; WX 77X series; WX-340

Latest Information Update: 22 Apr 2014

Price : $50

At a glance

  • Originator Wilex
  • Developer WILEX AG
  • Class Small molecules
  • Mechanism of Action Urokinase-type plasminogen activator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 14 Apr 2014 Discontinued - Preclinical for Solid tumours in Germany (PO)
  • 22 Apr 2009 Pharmacodynamics data from a preclinical study in Cancer presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR-2009)
  • 22 Feb 2005 Early research in Solid tumours in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top